Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy and Diagnosis

Factors affecting 131I therapy radiation dose

Kenneth Nichols, Maria-Bernadette Tomas, Gene Tronco, Fritzgerald Leveque, Kuldeep Bhargava and Christopher Palestro
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1515;
Kenneth Nichols
1Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria-Bernadette Tomas
1Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gene Tronco
1Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fritzgerald Leveque
1Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuldeep Bhargava
1Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Palestro
1Donald & Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1515

Purpose: Administration of the same empiric amount of activity of 131I to all pts to treat thyroid cancer may inadvertently deliver more than 200 cGy radiation dose (D) to blood, which is considered excessive. Reasons for pts to be referred for 131I dosimetry include: impaired renal function, abnormal pathology findings, age < 16 yrs, rising thyroglobulin levels, & metastatic disease to lungs, to bones or to both. Our study was undertaken to determine which of these factors had the highest likelihood of excessive radiation dose if an empiric amount of 131I were to be administered, & to determine if the presence of multiple factors increased that likelihood.

Methods: Data were examined retrospectively of 123 pts (age = 58±18 years; 62 female pts; 61 male pts) with thyroid cancer who underwent blood sample collection over 4-7 days following ingestion of 37-148 MBq (1-4 mCi) 131I, & whole-body 131I scanning 48 hrs after administration of 131I. Impaired renal function was defined as BUN & creatinine values exceeding normal limits. 131I blood-measurement-only dosimetry was used to compute 131I D. The % of pts for whom D > 200 cGy for an empiric amount of administered activity of 7.4 GBq (200 mCi) 131I were tabulated. Results: Among the 123 pts, 62 had only one factor, for whom reasons for referral had significantly different D values (ANOVA F-factor = 4.2, p = 0.003). The single factor with greatest D was impaired renal function (D = 210±65 cGy, N = 7) & the one with lowest D was rising thyroglobulin levels (87±31 cGy, N = 14). Among all pts increasing numbers of factors were significantly associated with different D values (ANOVA F-factor = 5.6, p = 0.001), & were significantly correlated with increasing D (Rank correlation ρ= 0.40, p < 0.001). Pts with more than 1 factor had significantly higher D than those with only 1 factor (199±109 versus 125±90 cGy, p = 0.0001). Conclusion: Pts referred for 131I dosimetry have significantly greater risk of exceeding blood dose limits if administered empiric activity with increasing numbers of involving factors, for which impaired renal function constitutes the single factor associated with greatest excessive radiation dose.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Factors affecting 131I therapy radiation dose
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Factors affecting 131I therapy radiation dose
Kenneth Nichols, Maria-Bernadette Tomas, Gene Tronco, Fritzgerald Leveque, Kuldeep Bhargava, Christopher Palestro
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1515;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Factors affecting 131I therapy radiation dose
Kenneth Nichols, Maria-Bernadette Tomas, Gene Tronco, Fritzgerald Leveque, Kuldeep Bhargava, Christopher Palestro
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1515;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis

  • Added value of single photon emission computed tomography (SPECT) / Computed Tomography (CT) with radioiodine whole body scan in follow up of patients with differentiated thyroid cancer
  • Thyroglobulin measurement in fine-needle aspiration optimize lateral neck dissection in patients with papillary thyroid cancer
  • Prognostic value of pre-and post-induction chemotherapy FDG PET/CT in locally advanced oropharyngeal cancer patients.
Show more Oncology: Clinical Therapy and Diagnosis

Endocrinology (Clinical Therapy) Posters

  • External Radiation Exposure Rates After [177Lu]DOTA-Octreotate Therapy
  • Feasibility of post-therapy quantitative Lu-177-DOTATATE SPECT/CT in patients with metastatic neuroendocrine tumor for evaluation of response to treatment: Comparison with Ga68-DOTATATE-PET/CT
  • Predictors of outcome in patients with neuroendocrine neoplasm (NEN) undergoing FDG PET prior to PRRT
Show more Endocrinology (Clinical Therapy) Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire